Literature DB >> 18505918

The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity.

Amanda L Willis1, Nhan L Tran, Julie M Chatigny, Nichole Charlton, Hong Vu, Sharron A N Brown, Michael A Black, Wendy S McDonough, Shannon P Fortin, Joshua R Niska, Jeffrey A Winkles, Heather E Cunliffe.   

Abstract

Genomic characterization is beginning to define a molecular taxonomy for breast cancer; however, the molecular basis of invasion and metastasis remains poorly understood. We report a pivotal role for the fibroblast growth factor-inducible 14 (Fn14) receptor in this process. We examined whether Fn14 and its ligand tumor necrosis factor-like weak inducer of apoptosis (TWEAK) were expressed in breast tumors and whether deregulation of Fn14 levels affected malignant behavior of breast cancer cell lines. Analysis of TWEAK and Fn14 in publicly available gene expression data indicated that high Fn14 expression levels significantly correlated with several poor prognostic indicators (P < 0.05). Fn14 expression was highest in the HER2-positive/estrogen receptor-negative (HER2(+)/ER(-)) intrinsic subtype (P = 0.0008). An association between Fn14 and HER2 expression in breast tumors was confirmed by immunohistochemistry. Fn14 levels were elevated in invasive, ER(-) breast cancer cell lines. Overexpression of Fn14 in weakly invasive MCF7 and T47D cells resulted in a marked induction of invasion and activation of nuclear factor-kappaB (NF-kappaB) signaling. Ectopic expression of Fn14tCT, a Fn14 deletion mutant that cannot activate NF-kappaB signaling, was not able to induce invasion. Moreover, ectopic expression of Fn14tCT in highly invasive MDA-MB-231 cells reduced their invasive capability. RNA interference-mediated inhibition of Fn14 expression in both MDA-MB-231 and MDA-MB-436 cells reduced invasion. Expression profiling of the Fn14-depleted cells revealed deregulation of NF-kappaB activity. Our findings support a role for Fn14-mediated NF-kappaB pathway activation in breast tumor invasion and metastasis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505918      PMCID: PMC3519279          DOI: 10.1158/1541-7786.MCR-08-0005

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  50 in total

Review 1.  Cancer metastasis: building a framework.

Authors:  Gaorav P Gupta; Joan Massagué
Journal:  Cell       Date:  2006-11-17       Impact factor: 41.582

Review 2.  Tumor metastasis: mechanistic insights and clinical challenges.

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2006-08       Impact factor: 53.440

Review 3.  Transcriptional regulation via the NF-kappaB signaling module.

Authors:  A Hoffmann; G Natoli; G Ghosh
Journal:  Oncogene       Date:  2006-10-30       Impact factor: 9.867

Review 4.  Nuclear factor-kappaB in cancer development and progression.

Authors:  Michael Karin
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

5.  Concordance among gene-expression-based predictors for breast cancer.

Authors:  Cheng Fan; Daniel S Oh; Lodewyk Wessels; Britta Weigelt; Dimitry S A Nuyten; Andrew B Nobel; Laura J van't Veer; Charles M Perou
Journal:  N Engl J Med       Date:  2006-08-10       Impact factor: 91.245

6.  Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome.

Authors:  Nhan L Tran; Wendy S McDonough; Benjamin A Savitch; Shannon P Fortin; Jeffrey A Winkles; Marc Symons; Mitsutoshi Nakada; Heather E Cunliffe; Galen Hostetter; Dominique B Hoelzinger; Jessica L Rennert; Jennifer S Michaelson; Linda C Burkly; Christopher A Lipinski; Joseph C Loftus; Luigi Mariani; Michael E Berens
Journal:  Cancer Res       Date:  2006-10-01       Impact factor: 12.701

Review 7.  Breast cancer metastasis: markers and models.

Authors:  Britta Weigelt; Johannes L Peterse; Laura J van 't Veer
Journal:  Nat Rev Cancer       Date:  2005-08       Impact factor: 60.716

8.  Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.

Authors:  Michael F Press; Guido Sauter; Leslie Bernstein; Ivonne E Villalobos; Martina Mirlacher; Jian-Yuan Zhou; Rooba Wardeh; Yong-Tian Li; Roberta Guzman; Yanling Ma; Jane Sullivan-Halley; Angela Santiago; Jinha M Park; Alessandro Riva; Dennis J Slamon
Journal:  Clin Cancer Res       Date:  2005-09-15       Impact factor: 12.531

Review 9.  Linkage between EGFR family receptors and nuclear factor kappaB (NF-kappaB) signaling in breast cancer.

Authors:  Debajit K Biswas; J Dirk Iglehart
Journal:  J Cell Physiol       Date:  2006-12       Impact factor: 6.384

10.  Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis.

Authors:  S Wang; M Zhan; J Yin; J M Abraham; Y Mori; F Sato; Y Xu; A Olaru; A T Berki; H Li; K Schulmann; T Kan; J P Hamilton; B Paun; M M Yu; Z Jin; Y Cheng; T Ito; C Mantzur; B D Greenwald; S J Meltzer
Journal:  Oncogene       Date:  2006-01-30       Impact factor: 9.867

View more
  40 in total

Review 1.  The TWEAK-Fn14 system as a potential drug target.

Authors:  Harald Wajant
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

2.  Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer.

Authors:  Francesc Xavier Avilés-Jurado; Ximena Terra; David Gómez; Joan Carles Flores; Antoni Raventós; Elsa Maymó-Masip; Xavier León; Vicente Serrano-Gonzalvo; Joan Vendrell; Enric Figuerola; Matilde R Chacón
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-26       Impact factor: 2.503

Review 3.  Advances in anticancer immunotoxin therapy.

Authors:  Christine Alewine; Raffit Hassan; Ira Pastan
Journal:  Oncologist       Date:  2015-01-05

4.  Fn14 receptor promotes invasive potential and metastatic capacity of non-small lung adenocarcinoma cells through the up-regulation of integrin α6.

Authors:  J Jandova; C J Mason; S C Pawar; G S Watts
Journal:  Neoplasma       Date:  2015       Impact factor: 2.575

5.  Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway.

Authors:  Sharron A N Brown; Arundhati Ghosh; Jeffrey A Winkles
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

Review 6.  The TWEAK-Fn14 pathway: a potent regulator of skeletal muscle biology in health and disease.

Authors:  Marjan M Tajrishi; Timothy S Zheng; Linda C Burkly; Ashok Kumar
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-24       Impact factor: 7.638

7.  Structural basis and targeting of the interaction between fibroblast growth factor-inducible 14 and tumor necrosis factor-like weak inducer of apoptosis.

Authors:  Harshil Dhruv; Joseph C Loftus; Pooja Narang; Joachim L Petit; Maureen Fameree; Julien Burton; Giresse Tchegho; Donald Chow; Holly Yin; Yousef Al-Abed; Michael E Berens; Nhan L Tran; Nathalie Meurice
Journal:  J Biol Chem       Date:  2013-09-20       Impact factor: 5.157

8.  Development of human serine protease-based therapeutics targeting Fn14 and identification of Fn14 as a new target overexpressed in TNBC.

Authors:  Hong Zhou; Khalid A Mohamedali; Ana Maria Gonzalez-Angulo; Yu Cao; Mary Migliorini; Lawrence H Cheung; Janine LoBello; Xiudong Lei; Yuan Qi; Walter N Hittelman; Jeffrey A Winkles; Nhan L Tran; Michael G Rosenblum
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

9.  Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Authors:  Steffen Salzmann; Axel Seher; Johannes Trebing; Daniela Weisenberger; Alevtina Rosenthal; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

10.  The HER2- and heregulin β1 (HRG)-inducible TNFR superfamily member Fn14 promotes HRG-driven breast cancer cell migration, invasion, and MMP9 expression.

Authors:  Kaushal Asrani; Ruth A Keri; Rebeca Galisteo; Sharron A N Brown; Sarah J Morgan; Arundhati Ghosh; Nhan L Tran; Jeffrey A Winkles
Journal:  Mol Cancer Res       Date:  2013-02-01       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.